Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Click here to view

Careers
Clinical Trials
Contact

Science
Programs
Patients
Investors & Media
- Overview
- News Releases
- Events
- Presentations
- ESG
About

Science
Programs
Patients
Investors & Media
- Overview
- News Releases
- Events
- Presentations
- ESG
About

LinkedIn
Twitter

Uncategorized

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

Sign up for email alerts

Company

Science
Programs
Collaborations
Patients
About
Careers
Contact

Latest

News Releases
Events
Science Presentations
Scientific Publications
Corporate Presentations

Resources

Pipeline
Clinical Trials
Legal Disclaimer
Privacy Policy

Social

LinkedIn
X

© 2025 Sangamo Therapeutics